blog

This guide details COA structure (identity, quality, scientific data, compliance), verification checks, common errors, and future-proofing strategies like blockchain tracking. Request a sample COA to streamline your quality processes.

This expert-authored article compares TAF vs TDF, emphasizing chemical design, safety, & clinical benefits.

Chemical & pharma buyers: Fake COAs risk safety and compliance. Learn manual verification red flags + digital COA verification tools (supplier portals, QR codes, blockchain). Protect operations with trusted API/intermediate suppliers offering transparent, verifiable COAs.

This article explores the critical role of pharmaceutical intermediates manufacturers in global drug production, emphasizing GMP compliance, custom synthesis capabilities, and regulatory expertise. It guides readers on evaluating suppliers based on quality, innovation, and supply chain reliability to optimize API development.

Orforglipron, an oral GLP-1 agonist, overcomes injection limitations with 29-49h half-life and enzyme resistance. Phase II/III trials show 14.7% weight loss and 1.48% HbA1c reduction. Tianming Pharma provides certified intermediates.

Ergothioneine (EGT) delivers comprehensive skin benefits via antioxidant, anti-inflammatory, photoprotective, and collagen-stimulating actions.

Ergothioneine, hailed as the “Longevity Vitamin,” targets mitochondria via OCTN1 transporters, offering unparalleled antioxidant, anti-fatigue, and anti-aging effects. Tianming Pharma details L-form purity (>99.99%), glutathione synergy, and science-backed alternatives like NMN/PQQ.

Orforglipron’s non-peptide scaffold (23 atoms) enables oral GLP-1 therapy via acid-stable triazole core, (R)-chlorophenyl chiral targeting, and pyridine N-oxide H-bonding. Tianming Pharma provides key intermediates for scalable synthesis.

We have made a major breakthrough in the production of orforglipron intermediates. We now offer a range of orforglipron intermediates with detailed information. Please contact us for more information to meet your pharmaceutical needs.

This article examines six pivotal trends reshaping the 2025 pharma intermediates sector: Asia’s manufacturing evolution, continuous production adoption, AI-driven R&D acceleration, ESG compliance pressures, nearshoring strategies, and biomanufacturing breakthroughs.